<DOC>
	<DOC>NCT03031938</DOC>
	<brief_summary>A4091065 is a multicenter, prospective, cohort study with enhance physical an neurodevelopmental surveillance to characterize the outcomes related to the development of infants up to the age of 15 months who were potentially exposed to tanezumab, placebo or comparator via maternal exposure or in utero in any tanezumb study.</brief_summary>
	<brief_title>Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies</brief_title>
	<detailed_description>A4091065 is a long term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057, A4091058, A4091059, A4091061 or A4091063</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical study. The infant's mother (who was the tanezumab clinical study participant) must review, agree and sign an informed consent document explaining the details of the perinatal and post natal follow up. Where local regulations mandate, the male parent would also review and sign the informed consent. Parents or legal guardian must be willing and able to comply with scheduled visits and study procedures. There are no exclusion criteria for participating in this study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Exposure in utero in tanezumab program</keyword>
</DOC>